Statin Kullanan Hastaların Dişeti Oluğu Sıvısında Il-1Β, Il-10 Ve Miyeloperoksidaz Düzeylerinin Saptanması ve Klinik Parametrelerle Korelasyonu
Çiçek Ari, Vuslat
Üst veriTüm öğe kaydını göster
The aim of this study was to evaluate effects of statin treatment on IL (Interleukin)-1ß, IL-10 and myeloperoxidase (MPO) levels in gingival crevicular fluid of patients with hyperlipidemia and periodontal diseases. There were no published data regarding effects of statins on IL-10 and MPO in periodontal disease. Seventy nine subjects with hyperlipidemia and 48 systemically healty controls (C) were included in the study. Hyperlipidemic groups were divided into two groups as suggested diet (HD) and prescribed statin (HS). Patients were classified to three subgroups as periodontally healthy (h), gingivitis (g) and chronic periodontitis (p). Blood samples were collected for the measurement of triglyceride (TRG), total cholesterol (TC), low-density lipprotein (LDL), high-density lipoprotein (HDL), very low-density lipoprotein (VLDL) and fasting plasma glucose levels. Periodontal parameters including plaque index (PI), gingival index (GI), probing pocket depth (PPD), clinical attachment level (CAL), and percentage of bleeding on probing (BOP) were also evaluated. There were no significant differences in periodontitis and gingivitis groups according to GI and PI scores in sample sites. However, values of PPD in HSp were significantly lower than Cp group. BOP in HSg group was signicantly lower than HDg and Kg groups. While IL-1ß levels of the HSp group were significantly lower than HDp group, IL-10 levels of HSg were significantly higher than HDg group. Also MPO levels were significantly lower in HSg than Cg and HDg groups. To conclude, hyperlipidemia led to an increase in proinflammatory cytokines positively, in contrary the statin usage decreased the levels of IL-1ß and MPO which play important role in periodontal destruction. Furthermore statins increased IL-10 levels in GCF. It can be suggested that statins may take place as a host modulating agents to prevent or reduce the rate of progression of periodontitis.